ERBB2 and breast carcinoma: HER2-directed therapies such as trastuzumab therapy in patients with breast cancer resulted in a median survival of over 3 years [12], whereas the therapy led to a modest increase by approximately 4 months in the median survival of patients with gastric cancer [13].